Resources Repository
-
OrganizationWeb Portal 2024Agency for Healthcare Research and Quality (AHRQ)
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for …
The Agency for Healthcare Research and Quality (AHRQ) is the nation's lead federal agency for research on health care quality, costs, outcomes and patient safety. AHRQ is the health services research arm of the U.S. Department of Health and Human Services (HHS), complementing the biomedical research mission of its sister agency, the National Institutes of Health. The agency is home to research centers that specialize in major areas of health care research, including: clinical practice…
Test Performance | Policy/Regulation | Infectious Diseases | Costing Methods | Health Outcomes | Decision Analysis | Cost-Effectiveness Analysis | Technology Assessment | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | North America -
DataWeb Portal 2024Healthcare Cost and Utilization Project (HCUP)
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in …
The Healthcare Cost and Utilization Project (HCUP) is the most comprehensive source of hospital data in the United States, including information on in-patient care, ambulatory care, and emergency department visits. HCUP enables researchers, insurers, policymakers and others to study health care delivery and patient outcomes over time, and at the national, regional, State, and community levels. The Agency for Healthcare Research and Quality (AHRQ) provides a range of data resources in the form of online, searchable…
Test Performance | Policy/Regulation | Infectious Diseases | Costing Methods | Health Outcomes | Evidence Synthesis | Cost-Effectiveness Analysis | Technology Assessment | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Health Systems | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | North America -
OrganizationWeb Portal 2024ISPOR
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics …
Founded in 1995 as an international multidisciplinary professional membership society, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) exists to advance the policy, science, and practice of pharmacoeconomics (health economics) and health outcomes research. ISPOR publishes Value in Health, which contains original research articles in the areas of economic evaluation, outcomes research, and conceptual, methodological, and health policy articles. Beyond health economics and outcomes research resources, tools of ISPOR include strategic initiatives, publications, and member…
Policy/Regulation | Infectious Diseases | Preferences/Values | Priority Setting/Ethics | Costing Methods | Health Outcomes | Value of Information | Mathematical Models | Cost-Effectiveness Analysis | Technology Assessment | Operations Research | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Health Systems | Business/Industry | Economics/Finance | Health/Medicine | Science/Technology | Global -
Resource PortalWeb Portal, Teaching Resource 2024MIDAS
MIDAS is a collaborative network of research scientists who use computational, statistical and mathematical models …
MIDAS is a collaborative network of research scientists who use computational, statistical and mathematical models to understand infectious disease dynamics and thereby assist the nation to prepare for, detect and respond to infectious disease threats. Midas focuses on research topics such as: Dynamics of emergence and spread of pathogens; Identification and surveillance of infectious diseases; Effectiveness and consequences of intervention strategies; Host/pathogen interactions; Ecological, climatic, economic and evolutionary dimensions of infectious diseases; The roles of behavior and behavioral adaptation in…
Policy/Regulation | Infectious Diseases | Mathematical Models | Dynamic Transmission | Calibration/Validation | Dynamic Simulation | Risk Analysis | Cost-Effectiveness Analysis | Technology Assessment | Health Systems | Climate/Environment | Health/Medicine | Science/Technology | Global | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Conceptual Mapping | Quantitative Literacy -
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
State-Transition | Policy/Regulation | Infectious Diseases | Mathematical Models | Benefit-Cost Analysis | Business/Industry | Economics/Finance | Government/Law | Health/Medicine | North America -
ArticlePublication 2022Vaccinations versus Lockdowns to Prevent COVID-19 Mortality
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly …
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly available datasets from the Israeli Ministry of Health were used to model the parameters of the pandemic in Israel. The Oxford COVID-19 Government Response Tracker was used for quantitative data on government policies. Data on the Israeli economy were taken from the Central Bureau of Statistics. The models demonstrate that the first lockdown prevented 1022 COVID-19 deaths at the cost…
State-Transition | Policy/Regulation | Infectious Diseases | Decision Theory | Costing Methods | Health Outcomes | Decision Analysis | Economics/Finance | Government/Law | Health/Medicine | Middle East & North Africa -
ArticlePublication 2022COVID-19 Response: The Need for Economic Evaluation
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be …
COVID-19-related policies are fraught with trade-offs. Many of these trade-offs involve dimensions that can be quantitatively weighed using economic evaluation, such as those between health and cost outcomes. Other types of dimensions, such as those involving equity or autonomy, can be harder to quantify but should be considered in a comprehensive health policy decision-making context nonetheless. The authors of this New England Journal of Medicine Perspectives article outline how methods of economic evaluation and decision…
Policy/Regulation | Infectious Diseases | Priority Setting/Ethics | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Economics/Finance | Health/Medicine | Global | North America -
ArticlePublication 2022Emerging Therapies for COVID-19: The Value of Information From More Clinical Trials
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face …
The COVID-19 pandemic necessitated time-sensitive policy and implementation decisions regarding new therapies in the face of uncertainty. This study aimed to quantify consequences of approving therapies or pursuing further research. The authors used a cohort state-transition model for hospitalized patients with COVID-19 to estimate quality-adjusted life-years (QALYs) and costs associated with multiple drug regimens and usual care. For each they assessed immediate approval, use only in research, emergency use authorization or reject. They conducted cost-effectiveness…
State-Transition | Policy/Regulation | Infectious Diseases | Value of Information | Benefit-Cost Analysis | Economics/Finance | North America | Europe -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Test Performance | Policy/Regulation | Infectious Diseases | Probability/Bayes | Technology Assessment | Health Systems | Government/Law | Health/Medicine | Global | North America